The "discordant doppelganger dilemma": SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?
J Hum Hypertens
.
2021 Aug;35(8):649-656.
doi: 10.1038/s41371-021-00482-y.
Epub 2021 Feb 9.
Authors
Scott W Murray
1
2
,
Sean McKelvey
3
,
Thomas D Heseltine
4
,
George Henderson
5
,
Jagdeep Singh
6
,
David Unwin
7
,
Adrian J B Brady
8
Affiliations
1
Wirral University Teaching Hospital, Wirral, UK. scottmurray@doctors.org.uk.
2
Liverpool Centre for Cardiovascular Science, Liverpool, UK. scottmurray@doctors.org.uk.
3
Institute for personalized therapeutic nutrition, Kelowna, BC, Canada.
4
Liverpool Centre for Cardiovascular Science, Liverpool, UK.
5
PreKure, Auckland, New Zealand.
6
Edinburgh Royal Infirmary, Edinburgh, UK.
7
The Norwood Surgery, Southport, UK.
8
University of Glasgow, Glasgow, Scotland, UK.
PMID:
33564065
PMCID:
PMC8373610
DOI:
10.1038/s41371-021-00482-y
No abstract available
MeSH terms
Carbohydrates
Diabetes Mellitus, Type 2*
Humans
Sodium-Glucose Transporter 2 Inhibitors*
Substances
Carbohydrates
Sodium-Glucose Transporter 2 Inhibitors